Literature DB >> 28479348

Large porous particles for respiratory drug delivery. Glycine-based formulations.

A G Ogienko1, E G Bogdanova2, N A Trofimov3, S A Myz4, A A Ogienko5, B A Kolesov6, A S Yunoshev7, N V Zubikov3, A Yu Manakov6, V V Boldyrev8, E V Boldyreva9.   

Abstract

Large porous particles are becoming increasingly popular as carriers for pulmonary drug delivery with both local and systemic applications. These particles have high geometric diameters (5-30μm) but low bulk density (~0.1g/cm3 or less) such that the aerodynamic diameter remains low (1-5μm). In this study salbutamol and budesonide serve as model inhalable drugs with poor water solubility. A novel method is proposed for the production of dry powder inhaler formulations with enhanced aerosol performance (e.g. for salbutamol-glycine formulation the fine particle fraction (FPF≤4.7μm) value is 67.0±1.3%) from substances that are poorly soluble in water. To overcome the problems related to extremely poor aqueous solubility of the APIs, not individual solvents are used for spray freeze-drying of API solutions, but organic-water mixtures, which can form clathrate hydrates at low temperatures and release APIs or their complexes as fine powders, which form large porous particles after the clathrates are removed by sublimation. Zwitterionic glycine has been used as an additive to API directly in solutions prior to spray freeze-drying, in order to prevent aggregation of powders, to enhance their dispersibility and improve air-flow properties. The clathrate-forming spray freeze-drying process in the multi-component system was optimized using low-temperature powder X-ray diffraction and thermal analysis.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Budesonide; Clathrate hydrates; Dry powder inhaler formulation; Glycine; Large porous particles; Salbutamol; Spray freeze-drying

Mesh:

Substances:

Year:  2017        PMID: 28479348     DOI: 10.1016/j.ejps.2017.05.007

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  7 in total

1.  Inhalable Nanocomposite Microparticles with Enhanced Dissolution and Superior Aerosol Performance.

Authors:  Chune Zhu; Jianting Chen; Shihui Yu; Chailu Que; Lynne S Taylor; Wen Tan; Chuanbin Wu; Qi Tony Zhou
Journal:  Mol Pharm       Date:  2020-07-24       Impact factor: 4.939

2.  Inhalable Protein Powder Prepared by Spray-Freeze-Drying Using Hydroxypropyl-β-Cyclodextrin as Excipient.

Authors:  Jason C K Lo; Harry W Pan; Jenny K W Lam
Journal:  Pharmaceutics       Date:  2021-04-24       Impact factor: 6.321

3.  Microencapsulated Isoniazid-Loaded Metal-Organic Frameworks for Pulmonary Administration of Antituberculosis Drugs.

Authors:  Cristina Fernández-Paz; Estefanía Fernández-Paz; Pablo Salcedo-Abraira; Sara Rojas; Sheila Barrios-Esteban; Noemi Csaba; Patricia Horcajada; Carmen Remuñán-López
Journal:  Molecules       Date:  2021-10-23       Impact factor: 4.411

4.  Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline.

Authors:  Si Nga Wong; Jingwen Weng; Ignatius Ip; Ruipeng Chen; Richard Lakerveld; Richard Telford; Nicholas Blagden; Ian J Scowen; Shing Fung Chow
Journal:  Pharmaceutics       Date:  2022-01-27       Impact factor: 6.321

Review 5.  Is there room for further innovation in inhaled therapy for airways disease?

Authors:  Martyn F Biddiscombe; Omar S Usmani
Journal:  Breathe (Sheff)       Date:  2018-09

6.  Immunogenicity of glycine nanoparticles containing a chimeric antigen as Brucella vaccine candidate.

Authors:  Ghazal Karevan; Kazem Ahmadi; Ramezan Ali Taheri; Mahdi Fasihi-Ramandi
Journal:  Clin Exp Vaccine Res       Date:  2021-01-31

7.  Clathrate Hydrates of Organic Solvents as Auxiliary Intermediates in Pharmaceutical Research and Development: Improving Dissolution Behaviour of a New Anti-Tuberculosis Drug, Perchlozon.

Authors:  Andrey G Ogienko; Svetlana A Myz; Andrey A Nefedov; Anna A Ogienko; Tatyana P Adamova; Olga M Voronkova; Svetlana V Amosova; Boris A Trofimov; Vladimir V Boldyrev; Elena V Boldyreva
Journal:  Pharmaceutics       Date:  2022-02-24       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.